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Abstract
Because the choroid plexus normally controls the production and composition of cerebrospinal
fluid and as such, its many functions of the central nervous system, we investigated whether
ligand-mediated targeting could deliver genes to its secretory epithelium. We show here that when
bacteriophage are targeted with epidermal growth factor, they acquire the ability to enter choroid
epithelial cells grown in vitro as cell cultures, ex vivo as tissue explants or in vivo by intra-cerebro-
ventricular injection. The binding and internalization of these particles activates EGF receptors on
targeted cells and the dose-, and time- dependant internalization of particles is inhibited by the
presence of excess ligand. When the phage genome is further re-engineered to contain like green
fluorescent protein or firefly luciferase under control of the cytomegalovirus promoter, gene
expression is detectable in the choroid plexus and ependymal epithelium by
immunohistochemistry or by non-invasive imaging respectively. Taken together, these data
support the hypothesis that re-engineered ligand-mediated gene delivery should be considered a
viable strategy to increase the specificity of gene delivery to the central nervous system and
bypass the blood brain barrier so as to exploit the biological effectiveness of the choroid plexus as
a portal of entry into the brain.
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1. INTRODUCTION
Of the many strategies to defeat the blood brain barrier (Johanson et al., 2005; Misra et al.,
2003; Neuwelt et al., 2008; Pardridge, 2007a; Pardridge, 2007b; Patel et al., 2009;
Schlachetzki et al., 2004; Soderquist and Mahoney, 2010), few have focused on the unique
biological and biophysical features of the choroid plexus (CP), its intrinsic ability to produce
cerebrospinal fluid (CSF) and its capacity to deliver bioactive proteins. Over the last several
years however, there are a number of isolated reports that have begun to investigate the
prediction that it could be an important window for drug delivery into the CNS (Johanson et
al., 2005; Stopa et al., 2001). Herenu et al (Herenu et al., 2007), exploited an early
observation by Bajocchi et al (Bajocchi et al., 1993) describing how adenoviral icv
injections transduce ependymal and CP epithelial cells. Because an ependymal route for
insulin like growth factor-1 (IGF-1) gene delivery circumvents the need to transport IGF-1
from blood and eliminates the need for repeated IGF-1 injections icv (Carro et al., 2000;
Carro et al., 2005), an ependymal route of IGF-1 gene delivery could be an effective
approach for therapeutics delivery.
While the mechanisms through which the biologically active molecules in CSF arrive at
their targets in parenchyma is remains controversial (Bickel et al., 2001; Brown et al., 2004;
Patel et al., 2009; Soderquist and Mahoney, 2010; Vigh and Vigh-Teichmann, 1998; Vigh et
al., 2004), there are unequivocal data showing that CSF is rich in biologically active
peptides (Veening and Barendregt, 2010). The introduction of biotherapeutics into CSF can
have dramatic biological effects on CNS function (Guan et al., 1996; Guan et al., 2001) but
there remain significant hurdles to delivering drugs into CSF. In as much as neuroactive
peptides regulate tissue function through the CNS, they can be widely distributed if they can
access CSF (Veening and Barendregt, 2010). Accordingly, CNS active drugs might use the
choroid plexus as a direct entry into CSF, biotherapeutic proteins might target the CP to alter
its function or alternatively genes might be targeted to CP so that the CP now produces
factors into CSF to alter CNS function. In all three cases, CP epithelial cell targeting is
required and in the latter, a capacity to transduce CP epithelial cells.
To this end, we and several other investigators have been using phage display to identify and
characterize ligands capable of cell-targeting for the purpose of specific gene
delivery(Harbottle et al., 1998; Larocca et al., 1998; Larocca et al., 2002; Li et al., 2001;
Poul and Marks, 1999). To date, naturally occurring ligands like epidermal growth factor
(EGF), fibroblast growth factor (FGF) and integrin-related peptides (RGD) have been shown
capable of delivering genes to cells using phage-based vectors.
In as much as ependymal and CP epithelia express EGF receptors (Danilov et al., 2009; Hall
et al., 1990; Kuhn and Miller, 1996), we explored whether EGF might be a suitable agent to
increase targeting specificity to choroid epithelium for drug delivery to CSF. We
demonstrate that (1) EGF phosphorylated receptors can be localized to epithelial cells of the
choroid plexus in vitro, ex vivo and in vivo, that (2) EGF-targeted phage show specific and
selective targeting of the choroid plexus epithelium in vitro, ex vivo and in vivo and that (3)
when these phage are engineered to also contain reporter genes like GFP and firefly
luciferase, then the EGF-targeted phage can transduce the CNS epithelia in ependyma and
choroid plexus in vivo. The possibility that these targeted phage might themselves be
candidates to re-engineer specific CNS-gene delivery vectors is discussed.
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2. RESULTS
EGF targeting of choroid plexus in vitro
Because of the epithelial nature of the blood-CSF barrier, it seemed reasonable to evaluate
the possibility that EGF could target particles to epithelial cells of the mouse and rat CP.
Accordingly, epithelial cells of a rat CP cell line (Hosoya et al., 2004; Kitazawa et al., 2001)
were grown in culture as described in the Materials and Methods, and an anti-
phosphorylated EGF receptor (EGFR) antibody used to confirm that these cells, when
stimulated by EGF, express an activated EGFR. As shown in Figure 1A, the EGF receptor is
activated by the EGF-targeted phage and targeted cells appear immunopositive for phospho-
EGF receptor thereby supporting our hypothesis that the EGFR is the portal of entry for
EGF displaying phage in the CP. When the EGF-targeted phage were incubated with these
cells, the phage were internalized by the cells (Figure 1B) and importantly, untargeted phage
did not internalize when they were incubated with CP cells (Figure 1C). Finally, when cells
were pre-incubated with the EGF-ligand so that the EGFR were occupied and down
regulated (Figure 1D), the targeted phage failed to enter cells and no internalization is
observed.
EGF-targeting of phage to the cultured CP cells is also dose (Figure 2) and time dependant
(Figure 3). As compared to controls, as little as 109 phage particles are needed to visualize
internalization. We also found that it was critical that contaminating endotoxins and
lipopolysaccharide (LPS) be removed from the phage preparation as they causes cell ruffling
of membranes in vitro and in vivo and as such an increase non-specific particle entry and
increases background signal. For this reason all experiments were performed comparing
internalization with the highest untargeted particle concentrations. The time course of
internalization (Figure 3) reinforced the notion that binding was specific as cell surface
labeling decreased as internalization signal increased. By 48 hours, phage immunoreactivity
was undetectable inside cells due to degradation of intact phage particles.
EGF targeting of choroid plexus ex vivo
With the knowledge that EGF could target the choroid epithelial cells in vitro, it then
seemed reasonable to evaluate the possibility that EGF could also target these epithelial cells
ex vivo and ensure that EGFR expression was not an artifact of cell culture. CP were
harvested as described in the Materials and Methods, and immunostaining with
commercially available anti-phosphorylated EGFR antibodies used to generate
immunohistochemical evidence that the EGF receptor is normally expressed in the rat
choroid plexus. As shown in Figure 4A, many but not all cells in the CP explants appeared
immuno-positive for phosphorylated EGFR supporting our hypothesis that the EGF receptor
could be used as a portal of entry for particle targeting to the CP. As shown in Figure 4B,
when the EGF-targeted phage were incubated with these explants over 2 hours, we obtained
immunohistochemical evidence that they have the ability to specifically internalize the EGF-
phage. Again, untargeted phage did not internalize when they were incubated with CP
explants (Figure 4C). Furthermore, when explants were pre-incubated with EGF so that the
EGFR are occupied by the ligand (Figure 4D), the EGF-targeted phage failed to enter cells
and the immunoreactive signal was significantly decreased.
EGF targeting of particles to CP explants was also dose (Figure 5) dependant. As compared
to controls, as little as 109particles were needed to visualize internalization into epithelial
cells. As with TRCSF-B cells in culture however (Figure 2), when higher concentrations of
phage were used, there was an increase in non specific entry of untargeted phage into cells
of the explant. Similarly, we found that it was critical that LPS be removed from the phage
preparation to avoid this non-specific background.
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EGF targeting of choroid plexus in vivo
When EGF-targeted or untargeted phage were injected ICV into rat brain, we had the
opportunity to evaluate target selectivity of the phage to determine the scope of cell targets
in vivo. It was clear that an injection of EGF-targeted phage had the capacity to internalize
into the CP (Figure 6A) but there was also significant signal detected in the ependymal cell
lining of the ventricles (Figure 6B). In contrast, there was little, if any, signal in the CP
(Figure 6C) or ependymal cells (Figure 6D) of animals treated with untargeted phage.
Occasional cells showed phage immunoreactivity that appeared to correlate with the cilia-
associated, macrophage-like cells in the CP (McMenamin, 1999). There was also a
significant immunohistochemical signal at the site of injection and along the needle track,
presumably due to injury-induced expression of EGFR. Little non-specific signal was
detected at the site of injection that could not be attributed to injury induced inflammatory
cells.
EGF-mediated transduction of choroid plexus and ependyma in vivo
We exploited the fact that the constructs of phage and EGF-targeted phage were engineered
to contain the green fluorescent protein (GFP) under control of the cytomegalovirus (CMV)
promoter. Accordingly, we used anti-GFP antibodies to evaluate whether there was any
evidence for transduction of cells targeted by the EGF-phage. As shown in Figure 7, GFP
positive cells were detected in the CP epithelium (Fig 7A), the epithelial cells of the lateral
(Figure 7B) and third (Figure 7C) ventricles. No GFP was detected in untargeted phage
treated animals (Figure 7D). Although few cells are transduced, particularly when compared
to the effects of adenovirus, we explored whether in vivo we might be able to detect
transduction non-invasively using a method to detect bioluminescence induced by luciferase
gene expression. To this end, the phage particle was re-engineered so that the GFP gene was
removed and substituted by the firefly luciferase gene but still under control of the CMV
promoter. When this phage is added to EGF target cells, there is was a significant light
signal generated by luciferase transgene expression that is was not present in cells treated
with untargeted phage. Pre-treating cells with camptothecin, an inhibitor of topisomerase
increased transduction (Burg et al., 2002) also gave a dose dependant increase in light
detection to cells in culture (Figure 7A). Accordingly, it was used to enhance signaling in
vivo while cyclosporine used to decrease drug transport out of the brain. Using non-invasive
imaging of luciferase activity, significant light signal was detected in the brains of EGF-
targeted but not untargeted phage (Figure 7B/C). Although lower the signal generated by the
positive control of the fluc gene delivered in adenovirus (Panel D), transduction was
detectable and significant above a negative control background obtained with untargeted
phage containing the fluc gene under control of the CMV promoter.
3. DISCUSSION
Several years ago, we proposed that it might be possible to target the CNS by exploiting the
unique features of the choroid plexus which exists at the interface between blood and CSF
(Johanson et al., 2005). If possible, we reasoned that drugs could either be designed to
translocate across the CP into CSF or, alternatively, to modify CP function so that the
composition of CSF was altered. After all, the regulation of different brain states can be
modulated by neuroactive substances that distribute through the CNS via CSF (Veening and
Barendregt, 2010). To this end, we show here that when phage are re-engineered to target
EGF receptor on the CP epithelium, they internalize into epithelial cells and that the
targeting is ligand specific, time and dose dependant and that it can lead to transduction of
target cells in vivo. The findings raise the possibility of using combinatorial techniques to
evolve a vector from these primordial particles that would be selectively and specifically
engineered for drug delivery to the CNS via CSF.
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In 1985, Smith (Smith and Petrenko, 1997) conceived of a method whereby short nucleic
acid sequences of DNA could be inserted into the coding sequence of the M13 phage glll
gene to generate particles that display a peptide-plll fusion protein. Reasoning that the
displayed peptides would confer phage with new intrinsic activities, he proposed that it
should be possible to introduce random and known sequences of DNA into the glll gene to
create particles with new activities. Over the last twenty years, we and other investigators
have been adapting this original phage display technique to identify novel peptides with
different specificities and activities for example, peptides have that confer physical stability
to particles in organic solvents like chloroform, decrease complement activation of
macromolecules in blood, modify immunogenicity, alter viral tropism in vitro and in vivo,
internalize particles into cells, transduce cells, promote transcytosis in vitro and in vivo and
even promote transmigration of particles across cell barriers in vitro and in vivo
(Muruganandam et al., 2002; Pasqualini and Ruoslahti, 1996b; Pasqualini and Ruoslahti,
1996c; Tanha et al., 2003; Vitiello et al., 2005; Yip et al., 1999). These biopanning
approaches have been used to characterize organ and cell homing peptides that can target the
vasculature and, parenchyma targeting peptides that can mediate transcytosis across
epithelial cells in vitro and cell surface antibodies that transmigrate phage across the blood
brain barrier. Our own laboratories’ focus has been to identify and exploit ligands that
internalize into target cells. To this end, we and others previously re-engineered phage
vectors for binding to mammalian cells and monitored their entry into cells by
immunohistochemistry for internalization, transfection for drug delivery PCR for DNA
delivery and transduction for gene expression (Barry et al., 1996; Burg et al., 2004;
Harbottle et al., 1998; Ivanenkov and Menon, 2000; Kassner et al., 1999; Koivunen et al.,
1999; Kolonin et al., 2004; Larocca et al., 1998; Mount et al., 2004; Pasqualini and
Ruoslahti, 1996a; Pasqualini, 1999; Poul and Marks, 1999; Rajotte et al., 1998; Trepel et al.,
2000).
Although we prove the concept of CP targeting with EGF, it is not clear that this ligand is
ideally suited for CP targeting. First, EGF has intrinsic activity and is a naturally occurring
growth factor. Second, EGF may be specific for epithelial cells in the brain as described
here, but there are several alternative cell types that express EGF receptors including
astrocytes, activated glia and endothelial cells. The specificity that we observe in vivo is
likely due to the compartmentalization of phage in the ventricular space while the specificity
in vitro due to the limited number of cell types available for targeting. Accordingly, it would
be useful to take a more traditional approach of phage display to mine libraries and identify
biologically inert targeting peptides capable of redirecting particles to the CP.
There are at least three processes that could exploit the central role of the choroid plexus in
the brain for drug delivery to the CNS (Figure 8). The first, more classical approach, is to
target the CP epithelium for direct drug translocation into CSF. This involves exploiting
cellular processes in the CP epithelia in the same way that has proposed exploiting receptors
in the blood brain barrier for translocation across brain endothelial cells into brain
parenchyma (Pardridge, 2007a;Pardridge, 2007b). Whereas the studies presented here
support the concept of CP-epithelial cell targeting, they were not aimed to demonstrate or
evaluate the translocation of EGF-particles across the barrier. The second approach to drug
targeting for CNS delivery through the CP epithelium is to treat the CP directly so as to alter
its function. Treatment of one cell could alter the function of its target and surrounding cells,
for example in terms of CSF production and composition. The fact that EGF can target
particles to CP epithelial cells certainly supports the concept that an EGF therapeutic might
alter CP function, but this was beyond the scope of the work presented here. Instead, the
mode of drug delivery we investigated is illustrated by the third approach. A gene is
delivered to the CP epithelium, either via blood or CSF, to alter CP function. Here, we show
that if the CP epithelium can be targeted (as with EGF in the experiments here), then the
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particles can be processed inside the cell to deliver, transcribe and transduce a gene
(luciferase and green fluorescent protein in the experiments here) and potentially modify the
epithelial cell’s function to make CSF and modify its composition. Because the studies here
demonstrate the feasibility of targeting and transduction epithelial cells from the luminal
(CSF) compartment, they support an initiative to achieve the same result via blood-borne
delivery.
The possibility of using the CP as a doorway into the CNS has gained momentum with the
difficulties in overcoming the blood brain barrier (Pardridge, 2007a; Pardridge, 2007b;
Schlachetzki et al., 2004). Indeed, most investigators propose using brain’s endothelium as a
target for CNS drug delivery because brain endothelial cells can be used to deliver bioactive
agents into the brain parenchyma. While the effects are certainly localized to the CNS, the
wide distribution of endothelium in the brain ensures wide distribution of drug if all
endothelia is targeted. But CNS barriers also provide different areas of the CNS differential
private milieus that open to the portal vasculature and CSF (Rodriguez et al., 2010). Herenu
et al however (Camihort et al., 2010; Herenu et al., 2009), used a different approach and
transduced ependyma so that cells now produce the growth factor IGF-1. In this case they
exploited the capacity of adenovirus to infect epithelial cells to increase the levels of IGF1 in
CSF and mimic the concentrations achieved by the injection of protein into CSF.
Presumably, adenoviral retargeting strategies that modify its pharmacokinetics, biological
activity and even potency could be used to improve its use as a gene delivery agent to the
CNS. Alternatively, it is interesting to speculate that with an introduction of targeting
ligands, the re-engineering of primordial particles might be possible so as to create de novo,
CNS-specific vectors for gene delivery. The observation reported here that the simple
targeting of a primordial particle like M13 bacteriophage with a ligand like EGF confers it
with a capacity to penetrate and transduce CP epithelia supports this hypothesis.
4. EXPERIMENTAL PROCEDURES
EGF display on phage
Phagemid were engineered with the sequence human EGF fused onto the gene encoding the
plll protein as described, prepared to titers of greater then 1013/ml with helper phage and
purified by PEG precipitation (Larocca et al., 2002). LPS was removed from all preparations
of phage using differential fractionation in detergent (Aida and Pabst, 1990). The resulting
purified phage average 2–3 copies of EGF displayed per particle as estimated by differential
immunoblotting with anti-plll and and anti-EGF antibodies. As indicated, the EGF displayed
on phage was prepared by fusion to amino acid 198 of plll (puc198EGF), amino acid 250 of
plll (puc250EGF) or there was no displayed ligand (puc198). No biological differences were
observed between EGF-targeted phage although yields of puc250EGF are somewhat higher.
Because both puc198 and puc198EGF plasmids also contain green fluorescent protein gene
driven by the CMV promoter (Kassner et al., 1999), the genome of each was used as the
starting material to substitute firefly luciferase (fluc) for GFP into the phage genome to
prepare puc198-fluc and puc198EGF-fluc. Briefly, the fluc gene was removed from the
pGL4.14-luc2 plasmid (Promega, Madison, WI) by Hindlll digestion, DNA polymerase I
and Large Klenow Fragment (KF) treatment followed by Xbal/Stul digestion. The fluc gene
was ligated into either the puc198 and puc198EGF plasmids that had their GFP gene excised
by BssH II digestion, treatment with KF, Xba I digestion and CIP treatment. XL1Blue MRF’
bacteria were transformed and grown overnight using standard molecular techniques and the
resulting plasmids were purified using the Qiagen plasmid DNA miniprep kit. Identity was
confirmed by restriction enzyme analyses with Attlll and Xbal digestions. Renilla luciferase
(rluc) was similarly ligated into the BssH II/KF treatment and Xbal excised puc198 and
puc198EGF plasmids using Hind III/KF treatment and Xba I digestion of the rluc excised
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from a pGL4.76-rluc plasmid (Promega, Madison, WI). Only the findings with puc198fluc
and puc198EGFfluc are reported here.
Culture of rat choroid plexus (CP) epithelial cells
We evaluated the effects of EGF targeting in vitro using an immortalized choroid plexus cell
line (TRCSFB cells) developed from transgenic Wistar rats (Kitazawa et al., 2001).
TRCSFB cells were plated on flasks coated with collagen type I (BD Biosciences) and
cultured in DMEM + GlutaMAX (Invitrogen) supplemented with 4.5g/L glucose, 5ml
Sodium Pyruvate (100mM, Invitrogen), 5ml NEAA (non-essential amino acids, x100,
(Invitrogen), 5ml Penicillin/Streptomycin (10,000 units/ml Penicillin, 10,000 g/ml
Streptomycin, Invitrogen), and 10% FBS (Sigma).
Preparation of explants of mouse and rat choroid plexus
As indicated in each experiment, adult C/57 black and Balb/C mice, or Wistar and Sprague
Dawley rats were killed with an intraperitoneral overdose of pentobarbital and brains
immediately dissected and placed in wet ice. All studies, protocols and procedures using
animals were approved by the Institutional Animal Care Use Committees. The CP was
harvested from 4th ventricle by carefully separating the cerebellum from the brain stem and
dissecting the choroid plexus from the roof of the cerebellum with tweezers. The lateral
ventricle CP were dissected after removal of the 4th ventricle’s CP by immersing the brain in
PBS and making two parallel sagital incisions 10 mm from the midline along the length of
the brain to a depth of 4mm so as to cut through the corpus callosum. The cortex was then
pulled away to the side exposing the lateral ventricles and choroid plexus. With a pair of
tweezers, each end of the CP was gently pulled away and placed in RPMI media containing
10% fetal calf serum (FCS) and 5% normal horse serum (NHS). Experiments with CP
explants were performed immediately after harvest.
Incubation with phage in vitro, ex vivo and in vivo
In vitro: TRCSF-B cells or primary cultures of PC3 cells were incubated at 37C in 95%CO2
controlled atmosphere with EGF-targeted or untargeted phage particles encoding the GFP or
luciferase gene under the control of the CMV promoter as indicated in each of the
experiments. Primary cultures of PC3 cells were treated with 1 or 10ug of camptothecin to
increase transduction and at 48hrs, cells were incubated for 5 min with luciferin in order to
visualize luciferase expression using a Lumina CCD Imaging system (Caliper Life Sciences,
Hopkinton, MA). Ex vivo: CP explants were incubated under the same conditions as
TRCSF-B cells but incubation time did not extended beyond 2 hours to ensure patency of
the epithelial cells. At the end of the indicated incubations, the cells or tissue were rinsed
first in 10 mM PBS containing Ca+2 and Mg+2, and then washed briefly in either 50mM
Glycine buffer pH 2.8 (cells in culture) or 10 mM PBS pH 7.4 containing 0.3% Tween 20.
The amount of phage bound and internalized was evaluated by immunohistochemistry.
To evaluate targeting in vivo, EGF-targeted and untargeted phage were injected ICV into
mice and rat brains as specifically indicated. All procedures involving the use of rats
followed strict adherence to Home Office guidelines, and with approval of the local ethics
committee while all mice ICV injections were approved by the institutional animal care and
use committee at the University of California San Diego. Thirty minutes prior to receiving
surgery, adult male Wistar (Charles River) rats (200–250g) received analgesia through a
subcutaneous injection of 0.03mg/kg buprenorphine. The rats were then anaesthetised using
5% isofluorane, delivered with O2 at 1.7L/min through a mask, and full anaesthesia was
maintained throughout the surgery.
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During surgery, the rat was immobilised in a stereotactic frame with the head elevated and
parallel to the table surface. A sagital incision was made along the midline of the scalp and
teased apart to expose the skull. The landmark at co-ordinates 0/0 that indicate Bregma
crossing the midline was marked using a fine marker pen. A small hole was drilled into the
skull 1.5mm lateral to the midline, 1mm posterior to Bregma. The needle of the Hamilton
syringe was inserted 4mm deep from the brain surface and 20μl of phage solution was
injected over 30 seconds. The syringe was left in the brain for one minute to prevent fluid
reflux. Once the ICV injection was complete the syringe was removed, the skin sutured and
the animal was taken off the anaesthetic and allowed to recover on a warm fleece bed. At
specific times after injection (24–72 hours), the rats were humanely killed by delivering
rising concentrations of CO2 and immediately perfused with 4% paraformaldehyde in PBS,
pH 7.4. The brains were dissected and post-fixed for 4h at 4 °C. The tissues were then
cryoprotected by placing them in raising concentrations of sucrose (10–30%) in PBS at 4 °C.
Tissues were embedded in OCT (RA Lamb Labs) and stored at −80C until required. Twelve
micron-thick coronal midbrain sections were mounted onto positive charged slides to
perform immunohistochemistry.
Immunohistochemistry and detection of internalized phage
Prior to fixation, CP cells in culture and CP tissue explants were rinsed in 50mM glycine
buffer pH 2.8 for 5 min or 10mM PBS pH 7.4 containing 0.3% Tween 20 (Sigma),
respectively. Cells and tissue samples were then rinsed in PBS (3X) and fixed for 20 min at
room temperature in 2.2% formaldehyde in 10mM PBS pH 7.4 containing 2% glucose and
0.02% sodium azide. Cells and explants were rinsed once with PBS, permeabilized in
methanol for 6 min, and washed twice again with PBS. Immunofluorescence and
immunoperoxidase staining techniques using antibodies to the coat protein M13 (fd) phage
were used to detect internalized phage in either cultured epithelial cells in vitro, CP tissue
explants or midbrain coronal brain sections after ICV injection of phage particles. To block
non specific staining, cells and tissue samples were incubated with PBS containing 1% BSA
(Jackson Immuno Research), 0.3% Tween 20 (Sigma), and 10% NGS (Jackson Immuno
Research) for 20 minutes at room temperature. Excess blocker solution was drained and
samples incubated with rabbit anti-M13 phage (1/200, Sigma) for 1h at room temperature.
For immunofluorescence staining, samples were then incubated for 45 min at room
temperature with Alexa 594 labelled goat anti-rabbit antibodies (Invitrogen). After washing
with PBS, cell and tissue samples were mounted using Vectashield mounting medium
containing DAPI (Vector Labs) and visualized under an epifluorescent microscope and
confocal microscopy. In some instances peroxidase staining was used to evaluate the
distribution of phage particles in the brain after ICV injection. In this instance, after
incubation of the tissues with rabbit anti-M13 phage antibodies, tissue sections were rinsed
and incubated with biotinylated goat anti-rabbit IgG (Vector) for 45 min at room
temperature. The tissue sections were rinsed in PBS and endogenous peroxidase quenched
by incubating the tissue sections in 0.3% hydrogen peroxide (Sigma) for 30 min, washed in
PBS, and incubated with ABC solution (ABC Kit, Vector Labs) for 30 min. Sections were
incubated in Diaminobenzidine (DAB, Vector Labs) for 5–7 min rinsed, dehydrated, cleared
in Histoclear and mounted. Immunostaining was visualized under bright field microscopy
and DIC optics (Zeiss Axioplan).
When specifically stated, we evaluated the co-localization of immunoreactive phage protein
with phosphorylated EGF receptor to demonstrate activation by targeted phage upon
internalization. Cells, explants or tissue sections were incubated with goat anti-
phosphorylated EGFR (Santa Cruz Biotechnology) at a dilution of 1:50 and processed as
described above for anti-M13 phage antibodies. Normal donkey serum was used for the
blocking solution and Alexa 594 donkey anti-goat (Invitrogen, San Diego CA) was used as a
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secondary labeled antibody to visualize staining by fluorescence and confocal microscopy as
indicated in the text. To localize GFP gene expression after ICV injection, brain sections
were incubated with mouse anti-GFP antibodies (1:200, Invitrogen, San Diego CA) and the
signal was detected using Alexa 488 goat anti mouse antibodies as described above.
Evaluation of targeting specificity
To determine whether the internalization of EGF-targeted phage was ligand-receptor
specific, we performed competition assays with synthetic EGF peptide. TRCSFB cells or
tissue explants were incubated for 2hr at 37C under 5% CO2 with EGF-targeted phage (1012
particles/ml) ten minutes after having added 200 ng synthetic mouse EGF (Invitrogen).
Non-invasive in vivo imaging of transduction
Mice were anesthetized with isofluorane and given an intra-peritoneal injection with 1.5mg
of the substrate D-luciferin (Caliper Life Sciences, Hopkinton, MA) in 150 μL in saline.
After allowing 5 minutes to attain steady state distribution kinetics of the injected substrate,
luciferase activity was measured in the still-anesthetized mice using a Lumina CCD Imaging
System. Light emitting images were acquired and data analyzed with Living Image software
(Version 3.0, Caliper Life Sciences, Hopkinton, MA). As necessary all animal images were
exposure matched by matching color bar upper and lower limits in each panel. Regions of
interest (ROI) showing bioluminescence in the head and matched sizes in the flank were
used for image acquisition. Each image was quantified in units of photons/sec/cm2/steradian
to obtain a fold change as defined by targeted over untargeted ROI signal.
RESEARCH HIGHLIGHTS
1. Epidermal growth factor can target particles through its receptor and into the
choroid plexus epithelium.
2. The choroid plexus can be exploited as a portal of entry into the brain.
3. When genes are re-engineered into targeted bacteriophage, they can transduce
the brain epithelia and ependyma.
4. It may be possible to direct the evolution of biological nanoparticles for
synthetic biology.
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Figure 1. Internalization of EGF-targeted phage is specific in CP cells in vitro
TR-CSFB cells were incubated with EGF-targeted (Panels A, B & D) or non targeted phage
(Panel C) (1×1012cfu/ml) for 2h at 37C. The cells were acid washed to remove any particles
on the cell surface, fixed and then immuno-stained with antibodies against phosphorylated
EGF-R (Panel A) or M13 phage (Panels B-D) as described in the text. Binding of primary
antibodies was detected using 594 Alexa-donkey anti goat (Panel A) or 488 Alexa-goat anti
rabbit antibodies (Panels B-D). Positive immunostaining for the phosphorylated form of the
EGFR receptor is observed in TR-CSFB cells after incubation with specific antibodies
(Panel A). Internalization of EGF-phage is observed in the cytoplasm of these cells (Panel
B). In contrast, no internalization is observed when the cells are incubated with untargeted
phage (Panel C). Internalization of EGF targeted phage is blocked in the presence of an
excess of EGF (Panel D). Cells were counterstained with DAPI to visualize the cell nuclei.
pEGFR: Red; M13 phage: Red; Cell nuclei: Blue.
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Figure 2. Internalization of EGF-Phage is dose dependant in CP cells in vitro
TR-CSFB cells were incubated with increasing concentrations of EGF-targeted phage for
2h, at 37C. Cells were immuno-stained with antibodies against M13 phage and detected
using 488 Alexa goat labeled secondary antibodies. EGF-phage is internalized by TR-CSFB
cells at high titers of phage (>1×1011 cfu/ml). Cells were counterstained with DAPI to
visualize the cell nuclei. M13 phage: Red; Cell nuclei: Blue.
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Figure 3. Internalization of EGF-Phage is time dependant in CP cells in vitro
TR-CSFB cells were incubated with EGF-targeted phage for 2h at 37C, media replaced and
cells returned to the 37C incubator. Cells were acid washed, immuno-stained with M13
antibodies and visualized using 488 Alexa labeled secondary antibodies. Cells were
counterstained with DAPI to visualize the cell nuclei. By 2h EGF-targeted phage is already
internalized and by 6h significant amounts of EGF-phage have translocated to the peri-
nuclear area. By 48h, there is a reduction in intracellular M13 staining although phage
particles are still detectable by 72h. M13 phage: Red; Cell nuclei: Blue.
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Figure 4. Internalization of EGF-targeted phage is specific in CP explants
Choroid plexus were dissected from the lateral and 4th ventricle and incubated with EGF-
targeted (Panels A, B &D) or non targeted phage (Panel C) at a concentration of 1×1012cfu/
ml for 2h at 37C. To remove any particles on the cell surface, the explants were washed with
PBS containing Tween 20, fixed and then immunostained with antibodies against
phosphorylated EGFR (Panel A) or M13 phage (Panels B-D). Binding of primary antibodies
was detected using 594 Alexa-donkey anti goat (Panel A) or 488 Alexa-goat anti rabbit
antibodies (Panels B-D). Positive immunostaining for the phosphorylated form of the EGFR
receptor was observed in the choroid epithelial cells after incubation with specific antibodies
(Panel A). Internalization of EGF-phage is observed in the cytoplasm of the epithelial cells
(Panel B). In contrast, no immunoreactivity is observed when the explants are incubated
with untargeted phage (Panel C). Internalization of EGF-targeted phage is blocked in the
presence of an excess of EGF (Panel D). Tissue explants were counterstained with DAPI to
visualize the cell nuclei. pEGFR: Red; M13 phage: Red; Cell nuclei: Blue.
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Figure 5. Internalization of EGF-targeted phage is dose dependant in CP explants
Choroid plexus explants were incubated with increasing concentrations of EGF-targeted
phage for 2h, at 37C and processed as described in the text. Cells were immunostained with
antibodies against M13 phage and the binding detected using 488 Alexa goat labeled
secondary antibodies. At low titers (1×1011 cfu/ml), the internalization EGF-targeted phage
is almost undetectable but significant increase of immunoreactive M13 internalization is
observed at 1×1012 cfu/ml. At a concentration of 5×1012 cfu/ml, almost all of choroid
epithelial cells in the explants are immunopositive. Cells were counterstained with DAPI to
visualize the cell nuclei. M13 phage: Red; Cell nuclei: Blue.
Gonzalez et al. Page 17
Brain Res. Author manuscript; available in PMC 2011 November 4.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. EGF-targeted phage is internalised 24h after ICV injection
EGF-targeted phage (Panels A & B) or untargeted phage (Panels C & D) were injected into
the lateral ventricle and 24h later rats were killed and brain sections immunostained with
anti-M13 antibodies. M13 immunoreactivity is observed in epithelial cells of the choroid
plexus (Panel A) and the ependyma (Panel B). No immunoreactivity is observed in these
tissues when untargeted phage was injected ICV. (Red: M13; Blue: DAPI).
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Figure 7. Gene expression after ICV injection
Panel (A) In vitro transduction: The EGF target PC3 cells were incubated with 1× 1011
untargeted or EGF-targeted phage that were both re-engineered as described in the text to
contain the firefly luciferase (f-luc) gene under the control of the CMV promoter. Duplicate
wells of cells were treated with 0, 1ug or 10 ug of camptothecin and either incubated with no
phage (Ctl), EGF-targeted phage containing GFP gene (A), EGF-targeted phage containing
f-luc gene (B) or untargeted phage containing the f-luc gene (C). After incubating cells for
48 hrs, a 5 minute incubation with luciferin enabled a Lumina CCD Imaging system to
visualize gene expression in cells treated with EGF-targeted phage (Row B) and, as
expected the response was dose dependant on cells treated with camptothecin. No signal was
observed in the absence of targeting (Row C) or when EGF-targeted particles do not contain
the luciferase gene Row A.
Panel B-F: Effects of ICV injection of EGF-targeted phage in vivo. Mice were injected icv
with 1×1012 untargeted or EGF-targeted phage-luc and in Panels B and D, transgene
expression of luciferase monitored on 48 hours later by Lumina CCD Imaging either non
invasively (Panel B) or after brain dissection (Panel C). To identify the cellular localization
of this gene expression similar experiments were performed with EGF-targeted phage-gfp
(Panel D and E) or untargeted phage-gfp (Panel F) which demonstrated cell expression of
GFP in ependymal cells and in isolated cells in the choroid plexus. Whereas a 4-fold lower
background signal could be quantified after luciferase activity imaging, immunostaining
localized this signal to macrophages and monocytes at the site of injection and not in
ependyma or choroid plexus (Panel F).
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Figure 8. Drug Delivery to the Central Nervous System Via Choroid Plexus
There are three modes of drug delivery to the CNS using the choroid plexus as a portal of
entry. The first (1) is direct whereby molecules are targeted and directly translocated across
the CP epithelial barrier to find their targets from within the CNS. A second (2) is illustrated
by entering and trateing the CP epithelium so that its capacity the produce and composition
of CSF is modified. These then find their targets in the CNS parenchyma. Finally the third
strategy, in the example here using gene delivery, results in longer term changes of the
choroid plexus, allows the epithelial cell to produce novel therapeutic factors itself and as
such can confer the epithelium with an ability to change the production and composition of
CSF. This latter process and the feasibility with luminal targeting (3) is demonstrated in the
results presented here.
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